Noxopharm
  • About Us
    • About Noxopharm
    • CEO's Message
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Our Network
    • Pharmorage
  • Technology
    • Technology Platforms
    • Chroma ™
    • Sofra ™
      • mRNA Vaccines
      • Autoimmune Disease
    • Veyonda ®
  • Clinical Trials
    • IONIC
    • Other Trials
      • DARRT
      • CEP
      • LuPIN
      • NOXCOVID
  • Publications
  • Investor Centre
    • Share Price
    • Presentations & Interviews
    • Annual Reports
    • Financial Reports
    • ASX Announcements
    • Corporate Governance
    • Investor Fact Sheet
    • Share Registry Information
  • Contact Us
    • Contact Us
    • Partnering
    • Working at Noxopharm
    • ASX Announcements Email Alerts
Publications
Publications

    Publications

    Filter by Year:2022 2020 2019 2018 2017 
    27-May-2022
    Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.

    Read More here.

    27-Apr-2022
    Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors

    Read More here.

    8-Apr-2022
    The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.

    177 Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial | Journal of Nuclear Medicine

    • 1

    Quick Links

    Location

    Noxopharm Limited
    Suite 71
    159 Ridgecrop Drive
    Castle Hill NSW 2154
    Telephone:
    + 61 2 9144 2223

    ABN
    50 608 966 123

    Contact us

    Email Shareholder enquiries:
    info@noxopharm.com
    Patient enquires:
    medical.information@noxopharm.com
    My shareholding:
    www.automicgroup.com.au

    Stay in Touch

    Which of the following group do you best fit?

     
    Privacy

    Email Alerts

    Subscribe to our Email Alerts

    Follow Us

    Copyright © Noxopharm
    Site Map Privacy Search
    Site by